STOCK TITAN

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Rhea-AI Summary

Cytokinetics (Nasdaq: CYTK) granted stock options and restricted stock units to 18 new employees on November 13, 2026. The awards cover options for 64,110 shares at an exercise price of $56.13 per share and 42,496 restricted stock units, payable in shares upon vesting. Options vest over four years and have a 10-year term; restricted stock units vest over three years. Vesting requires continued service.

Loading...
Loading translation...

Positive

  • None.

Negative

  • Minor point. Forward-looking: it has not happened yet and may not happen.64,110 stock options with a $56.13 exercise price create potential shareholder dilution.
  • Minor point. Forward-looking: it has not happened yet and may not happen.42,496 restricted stock units will settle in common shares upon vesting, diluting existing holders.

Key Figures

Stock options granted: 64,110 shares RSUs granted: 42,496 RSUs Employees receiving awards: 18 employees +4 more
Stock options granted
64,110 shares
Aggregate options granted to employees as an inducement to employment
RSUs granted
42,496 RSUs
To be settled in common shares upon vesting
Employees receiving awards
18 employees
Employment commenced in October and November 2026
Option exercise price
$56.13 per share
Equal to the company's closing price on November 13, 2026
RSU vesting schedule
40% / 40% / 20%
Over 3 years, on the first, second, and third anniversaries; subject to continued service
Option vesting period
4 years
One-quarter vests on the first anniversary, with the remainder in monthly installments
Option term
10 years
Term of the granted stock options

Key Terms

restricted stock units (rsus), nasdaq listing rule 5635(c)(4)
2 terms
restricted stock units (rsus) financial
"42,496 restricted stock units (RSUs) that will be settled in shares"
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
nasdaq listing rule 5635(c)(4) regulatory
"in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 13, 2026 it granted stock options to purchase an aggregate of 64,110 shares of common stock and 42,496 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 18 employees, whose employment commenced in October and November 2026 as a material inducement to their employment.

The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first anniversary of the applicable grant date, an additional 40% of the RSUs vesting on the second anniversary of the grant date and the final 20% vesting on the third anniversary of the grant date, in each case, subject to each respective employee’s continued service with the Company. The stock options that were granted are subject to an exercise price of $56.13 per share, which is equal to the closing price of the Company’s common stock on November 13, 2026 and will vest over 4 years, with 1/4th of the shares underlying the employee’s option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting in monthly installments at a rate of 1/48th of the shares underlying such stock options over the subsequent 36 months, subject to each respective employee’s continued service with the Company. The stock options have a 10-year term. These awards are subject to the terms and conditions of the Company's Amended and Restated 2004 Equity Incentive Plan and the applicable award agreements pursuant to which the awards were granted.

The stock options and RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

About Cytokinetics

Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO® (aficamten) is a cardiac myosin inhibitor approved in the U.S., China, European Union, United Kingdom and Canada for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Following positive results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the company plans to submit a Supplemental New Drug Application in Q4 2026. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.

Disclaimer 

Omecamtiv mecarbil and ulacamten are investigational medicines. They have not been approved nor determined to be safe or efficacious for any disease state or any indication by FDA or any other regulatory agency.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission particularly under the caption “Risk Factors” in Cytokinetics’ latest Annual Report on Form 10-K. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

MYQORZO® is a registered trademark of Cytokinetics in the U.S., the European Union, the United Kingdom and Canada.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Cytokinetics grant to new employees in November 2026?

Cytokinetics granted options to purchase 64,110 common shares and 42,496 restricted stock units to 18 employees on November 13, 2026. The awards were employment inducements for employees who started in October and November 2026.

What is the vesting schedule for Cytokinetics' November 2026 inducement awards?

Restricted stock units vest 40% on the first anniversary, 40% on the second and 20% on the third anniversary of the applicable grant date. Options vest one-quarter on the first anniversary, then 1/48th monthly over the subsequent 36 months. Both schedules require the employee's continued service.

Keep reading